Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace

Grp78/BiP ELISA kit, 3/14

March 2014—Enzo Life Sciences’ high-sensitivity Grp78/BiP ELISA kit is an endoplasmic reticulum-specific homologue of Hsp70, serving as a critical stress-sensing chaperone and regulator of the unfolded protein response (UPR). Grp78 helps fold misfolded proteins, prevent protein aggregation, and regulate protein degradation, synthesis, transportation, and oligomerization.

Clarient modifies SeqWright, 3/14

March 2014—Clarient Diagnostic Services, a GE Healthcare company, has modified its facility in Houston to support a full range of clinical diagnostic testing for cancer. The facility, which operates under the name SeqWright Genomic Services, is a CLIA-certified lab offering nucleic acid sequencing and genomics services.

Interpretation and reporting solution, 3/14

March 2014—Qiagen last year enrolled molecular diagnostics laboratories in an early access program to complete the development of a Web-based solution to deliver faster, easier-to-use, and high-confidence clinical interpretation and reporting of observed gene variants in data from NGS-based tests.

Linearity FD D-Dimer PathFast Immunoanalyzer, 3/14

March 2014—Audit MicroControls added the Linearity FD D-Dimer PathFast Immunoanalyzer, five levels, to its line of calibration verification/linearity products. It is intended to simulate human patient serum samples for the purpose of determining linearity, calibration verification, and verification of reportable range for D-dimer.

Research on spatial memory in bats wins Eppendorf & Science prize, 3/14

March 2014—Israeli scientist Michael Yartsev, PhD, CV Starr postdoctoral research fellow of the Princeton Neuroscience Institute at Princeton University, won the 2013 Eppendorf & Science Prize for Neurobiology. Dr. Yartsev uses an unusual animal model—the bat—to study the underlying neural mechanisms of spatial memory and navigation in the mammalian brain.

Phlebotomy seminars, 3/14

March 2014—The Center for Phlebotomy Education will conduct intensive three-day seminars in Indianapolis and San Francisco for those who train or manage phlebotomists. The event will provide strategies to help attendees reduce expenses by cultivating satisfied, long-term employees; cut costs through process improvement; nurture professionalism and responsibility among specimen-collection personnel; implement different learning styles to maximize teaching; and mentor students and new staff.

DNA dye system, 3/14

March 2014—Promega launched the QuantiFluor One dsDNA System, a sensitive, dsDNA-specific fluorescent dye for use in research and clinical workflows. The dye system is integrated into the Promega Quantus Fluorometer and GloMax detection instruments but is compatible with any fluorometer capable of measuring the appropriate fluorescence excitation and emission spectra.

Qiagen software chosen for translational genomics, 3/14

March 2014—The Mount Sinai Genetic Testing Laboratory and the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, New York City, have adopted Qiagen’s Ingenuity Variant Analysis solution for research and translational genomics applications related to characterizing and identifying rare diseases.

Genomic-based tests, 3/14

March 2014—BioTheranostics introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provides personalized diagnostic information and therapeutic guidance for metastatic cancer patients.

Tissue, ID micro arrays, 3/14

March 2014—Bio SB launched the Normal Human Tissue Micro Array and the Infectious Disease Cell Line Micro Array. The NH-TMA arrays are available in 11- or 23-core configurations, allowing testing of multiple tissues on one slide, and are validated for use with more than 100 antibodies in immunohistochemistry.